检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:陈大富 赵扬冰[1] 白绍槐[2] 史宗道四川大学华西医学中心临床流行病学教研室 蒋丽丽[3]
机构地区:[1]四川大学华西医院普外科 [2]四川大学实验动物中心 [3]四川大学华西医院病理科
出 处:《中国普外基础与临床杂志》2002年第5期300-302,共3页Chinese Journal of Bases and Clinics In General Surgery
摘 要:目的 探讨人参皂甙Rg3 (简称Rg3 )与化疗药物联合应用对人乳腺浸润性导管癌动物模型中肿瘤的生长及微血管密度的影响。方法 采用人乳腺浸润性导管癌癌株原位种植于 16只雌性裸鼠 ,随机均分成 4组 :联合用药组即环磷酰胺 (CTX) 16mg/ (kg·d) +Rg3 10mg/ (kg·d)、Rg3组 [10mg/ (kg·d) ]、CTX组 [16mg/ (kg·d) ]及对照组。自肿瘤接种第 5天开始 ,连续灌胃 5 5d ,脱颈处死 ,分别检测肿瘤的重量 ,并计数肿瘤内微血管密度 (MVD)。结果 Rg3组和CTX组对原位种植肿瘤的生长有明显的抑制作用 ,联合治疗组抑制肿瘤生长的作用明显优于Rg3组 ,且MVD也明显低于CTX组及对照组。结论 Rg3与CTX联合应用能抑制人乳腺癌的生长 ,降低肿瘤内的MVD。Objective To study the mechanism of reducing the intratumoral microvessel density (MVD) by Ginsenoside Rg3 (Rg3) combined with cytotoxic agent in xenotransplanted human breast infiltrating duct carcinoma in nude mice. [WT5”HZ]Methods [WT5”BZ]Sixteen female nude mice were randomly divided into 4 groups to receive cyclophosphamid (16 mg/kg,qd) combined with Rg3 (10 mg/kg, qd),Rg3(10 mg/kg,qd) alone,cyclophosphamid (16 mg/kg,qd) alone and 0.5% sodium carboxymethyl cellulose (0.5 ml,qd) respectively for 55 days. Breast cancer mass were weighed and sampled for light microscopic observation. The intra-tumor MVD was examined by immunohistochemical staining. [WT5”HZ]Results [WT5”BZ]The tumor weight of treated group was significantly lower than that of control group. The tumor weight of the Rg3 combined with CTX group was lower than that of Rg3 group. The MVD value of Rg3 group was significantly lower than that of CTX group and control group. The MVD was significantly reduced in the Rg3 combined with CTX group than that in the others.[WT5”HZ]Conclusion [WT5”BZ]Rg3 combined with CTX can inhibit the growth of xenotransplanted human breast infiltrating duct carcinoma, and reduce the intratumoral MVD. [WT5”HZ]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15